Evidence map›Paper›PMID 35745219›Full record

ArticleNutrients2022

Clinical and Metabolomic Effects of Lactiplantibacillus plantarum and Pediococcus acidilactici in Fructose Intolerant Patients

Piero Portincasa, Giuseppe Celano, Nadia Serale, Paola Vitellio, Francesco Maria Calabrese, Alexandra Chira, Liliana David, Dan L Dumitrascu, Maria De Angelis

Open access · goldAbstract read
In one paragraph

Article in Nutrients, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Frontiers in nutrition · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 2 countries.

Piero PortincasaClinica Medica "A. Murri", Department of Biomedical Sciences & Human Oncology, University of Bari Medical School, 70124 Bari, Italy.ORCID 0000-0001-5359-1471
Giuseppe CelanoDipartimento di Scienze del Suolo, della Pianta e Degli Alimenti, Università Degli Studi di Bari Aldo Moro, 70126 Bari, Italy.ORCID 0000-0002-3805-7681
Nadia SeraleDipartimento di Scienze del Suolo, della Pianta e Degli Alimenti, Università Degli Studi di Bari Aldo Moro, 70126 Bari, Italy.
Paola VitellioDipartimento di Scienze del Suolo, della Pianta e Degli Alimenti, Università Degli Studi di Bari Aldo Moro, 70126 Bari, Italy.
Francesco Maria CalabreseDipartimento di Scienze del Suolo, della Pianta e Degli Alimenti, Università Degli Studi di Bari Aldo Moro, 70126 Bari, Italy.ORCID 0000-0003-0176-7046
Alexandra Chira2nd Department of Internal Medicine, 'Iuliu Hatieganu' University of Medicine and Farmacy, 400012 Cluj-Napoca, Romania.
Liliana David2nd Department of Internal Medicine, 'Iuliu Hatieganu' University of Medicine and Farmacy, 400012 Cluj-Napoca, Romania.
Dan L Dumitrascu2nd Department of Internal Medicine, 'Iuliu Hatieganu' University of Medicine and Farmacy, 400012 Cluj-Napoca, Romania.
Maria De AngelisDipartimento di Scienze del Suolo, della Pianta e Degli Alimenti, Università Degli Studi di Bari Aldo Moro, 70126 Bari, Italy.ORCID 0000-0002-2010-884X
University of Bari Aldo Moro · ITIuliu Hațieganu University of Medicine and Pharmacy · RO

Funding

European Joint Programming Initiative "A Healthy Diet for a Healthy Life (JPI HDHL) INTIMIC - JPI
6 · The paper itself

Abstract

Fructose intolerance (FI) is a widespread non-genetic condition in which the incomplete absorption of fructose leads to gastro-intestinal disorders. The crucial role of microbial dysbiosis on the onset of these intolerance symptoms together with their persistence under free fructose diets are driving the scientific community towards the use of probiotics as a novel therapeutic approach. In this study, we evaluated the prevalence of FI in a cohort composed of Romanian adults with Functional Grastrointestinal Disorders (FGIDs) and the effectiveness of treatment based on the probiotic formulation EQBIOTA

Indexed as

Fructose IntoleranceGastrointestinal DiseasesPediococcus acidilacticiProbioticsAdultFructoseHumansMetabolomicsPediococcusFructosefructose intolerancefunctional gastrointestinal disordersintestinal barriermetabolomeshort-chain fatty acids

Identifiers

PMID35745219
PMCPMC9231202
OpenAlexW4283022074

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.